{"id":"enzira-vaccine","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site pain or erythema"},{"rate":"5-15","effect":"Myalgia"},{"rate":"5-10","effect":"Headache"},{"rate":"5-10","effect":"Fatigue"},{"rate":"1-5","effect":"Low-grade fever"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enzira contains inactivated (killed) influenza virus antigens that trigger both humoral and cellular immune responses. Upon vaccination, the immune system recognizes these antigens and generates protective antibodies and T-cell responses against circulating influenza strains, reducing the risk of infection and disease severity.","oneSentence":"Enzira is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against influenza virus strains.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:42:17.927Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Seasonal influenza prevention in adults"}]},"trialDetails":[{"nctId":"NCT00888381","phase":"PHASE4","title":"A Study to Assess the Immunogenicity and Safety of CSL's 2009 / 2010 Formulation of Enzira® Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Seqirus","startDate":"2009-05","conditions":"Influenza","enrollment":120},{"nctId":"NCT01863433","phase":"PHASE4","title":"A Study to Assess the Immunogenicity and Safety of a Trivalent Influenza Vaccine Containing the 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-05","conditions":"Influenza, Human","enrollment":120},{"nctId":"NCT01591837","phase":"PHASE4","title":"A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Seqirus","startDate":"2012-05","conditions":"Influenza, Human","enrollment":120},{"nctId":"NCT01857297","phase":"PHASE4","title":"A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira® Vaccine in Healthy Volunteers","status":"COMPLETED","sponsor":"Seqirus","startDate":"2013-05","conditions":"Influenza, Human","enrollment":120},{"nctId":"NCT01113580","phase":"PHASE4","title":"A Clinical Trial of CSL's 2010/2011 Formulation of Enzira® in a Healthy Adult Population","status":"COMPLETED","sponsor":"Seqirus","startDate":"2010-05","conditions":"Influenza","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":306030,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Afluria® vaccine"],"phase":"marketed","status":"active","brandName":"Enzira® vaccine","genericName":"Enzira® vaccine","companyName":"Seqirus","companyId":"seqirus","modality":"Biologic","firstApprovalDate":"","aiSummary":"Enzira is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against influenza virus strains. Used for Seasonal influenza prevention in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}